

ABBVIE LTD ABPI DISCLOSURE REQUIREMENTS ON TRANSFERS OF VALUE TO MEMBERS OF THE PUBLIC FOR FINANCIAL YEAR 2025

| Annual Disclosure of Contracted Services Provided by The Public | | | | | |
|---|--|---------|------------------|---|-------------|
| | Number of Members of the Public Contracted | Country | Support Provided | Description of Support | Total |
| Members of the public* | 7 | UK | Fees | Professional services such as: development of educational materials, speaker engagements with speaker services. | £145,360.00 |
| | | | Expenses | | £14,400.00 |
| Patients | 40 | UK | Fees | Services to provide patient insights, including activities such as: speaker engagements with speaker services, advisor role at advisory board meetings, patient stories, or patient education material development. | £7,908.48 |
| | | | Expenses | | £1,441.84 |
| Journalists | 5 | UK | Expenses | Support for educational meeting attendance | £8,970.65 |

*Members of the Public including Caregivers, Patient Advocates and Influencers

ABBVIE LTD TRANSPARENCY DISCLOSURE METHODOLOGICAL NOTES FOR REPORTING YEAR 2025

As a member company of European Federation of Pharmaceutical Industries and Associations (EFPIA) and Association of the British Pharmaceutical Industry (ABPI), **AbbVie Ltd** is committed to ensuring that the nature and scope of transfers of value (ToV) with UK members of the public are clear and transparent. Therefore, AbbVie has published applicable ToV provided directly or indirectly to UK members of the public for the 2025 calendar year.

This Methodological Note provides guidance on how AbbVie has recorded and publicly reported this information in aggregate in accordance with the current edition of the ABPI Code of Practice.

Reporting period / Reportable ToV:

The AbbVie Ltd 2025 disclosure includes applicable ToV during the period between 1st January and 31st December 2025. The applicable ToV relate to payments made within the disclosure period. Payments made from 1st January 2026 will be considered for the next report.

Transparency Acknowledgment from UK members of the public, including patients and journalists:

Agreements between AbbVie and UK members of the public relating to ToV, have a Transparency section which includes notification of AbbVie's Transparency disclosure obligations.

Cross Border Interactions:

These ToV include engagements between AbbVie Global/Europe and UK members of the public where these have occurred. For example, where UK members of the public participated in an AbbVie Global/European programme or activity.

Members of the Public Definitions:

Other Members of the Public including Caregivers and Patient Advocates

Description: Services completed by other members of the public including caregivers of patients, patient advocates and other reportable recipients to provide AbbVie with expert insights, perspectives, and feedback, including providing insights into their lived experiences and participating in photo shoots and video recordings.

Patients

Description: Services completed by patients to provide AbbVie with expert insights, perspectives, and feedback on the patient experience, including activities such as speaking at AbbVie-organised meetings, providing insights into their lived experiences, participating in advisory board meetings and in video or audio recordings.

Journalists

Description: Support to journalists to participate in educational meetings.

Models

Services completed by professional models to represent real individuals as part of relevant AbbVie campaigns, including participation in photoshoots.

Influencers

Services completed by patient or celebrity influencers to represent real individuals as part of relevant AbbVie activities, including participation in social media campaigns

ToV Definitions of Fees and Expenses:

Contracted Services: Fees such as:

- Speaking at AbbVie internal and external meetings
- Assistance with training
- Writing articles and/or publications
- Participating in advisory boards
- Advising on the design of clinical trials

Contracted Services: Expenses, such as:

- Flights
- Hotel
- Subsistence
- Other transportations costs (mileage, train, taxi, bus, underground, parking)

Date Methodology:

AbbVie followed the date methodology when determining which ToV are in scope for the current reporting cycle:

- **Event Date** is defined as the date the expense occurred. ToV related to the following categories will use the Event Date when determining applicability for current year reporting requirements (e.g., did the event occur within the reporting period 1st January to 31st December 2025).
 - » Fee for Service and Consultancy: Expenses
 - » Support to attend education meeting: Expenses
- **Paid Date** is defined as the date the payment was paid to the recipient. ToV related to the following categories use the Paid Date when determining applicability for current year reporting requirements (e.g., did the payment occur within the reporting period 1st January to 31st December 2025).
 - » Contracted services: Fees

Value Added Tax (VAT):

Where applicable, disclosure of payments does not include VAT.

Withholding Taxes:

Where applicable, for services provided in locations outside of United Kingdom, ToV amounts will be reported as outlined in the contract agreement.

Currency:

All information is reported in Pound Sterling (GBP).

Exchange Rate:

Where ToV were captured in foreign currency, amounts were converted to local currency based on AbbVie Treasury Monthly Average Rates.

Multi-year Contracts:

Activities with ToV crossing calendar years may have the contracted full amount disclosed using the date of last payment.